Targeting iNKT cells for the treatment of sickle cell disease.
about
The role of adenosine signaling in sickle cell therapeuticsSickle cell disease biochip: a functional red blood cell adhesion assay for monitoring sickle cell disease.Beneficial and detrimental role of adenosine signaling in diseases and therapyBiomarkers and recent advances in the management and therapy of sickle cell diseaseAdvances in sickle cell therapies in the hydroxyurea eraAdenosine receptors as drug targets--what are the challenges?Invariant natural killer T cells as sensors and managers of inflammation.A humanized monoclonal antibody specific for invariant Natural Killer T (iNKT) cells for in vivo depletionDeveloping understanding of the roles of CD1d-restricted T cell subsets in cancer: reversing tumor-induced defects.G protein-coupled adenosine (P1) and P2Y receptors: ligand design and receptor interactionsIL-15 protects NKT cells from inhibition by tumor-associated macrophages and enhances antimetastatic activity.Mouse Invariant Monoclonal Antibody NKT14: A Novel Tool to Manipulate iNKT Cell Function In Vivo.Neutrophils, platelets, and inflammatory pathways at the nexus of sickle cell disease pathophysiology.Beyond hydroxyurea: new and old drugs in the pipeline for sickle cell disease.Sickle cell vaso-occlusion causes activation of iNKT cells that is decreased by the adenosine A2A receptor agonist regadenosonSignaling through hepatocellular A2B adenosine receptors dampens ischemia and reperfusion injury of the liver.Ischemia and reperfusion--from mechanism to translation.Different subsets of natural killer T cells may vary in their roles in health and disease.Triterpenoid inducers of Nrf2 signaling as potential therapeutic agents in sickle cell disease: a review.Natural Killer T cell subsets in eutopic and ectopic endometrium: a fresh look to a busy corner.Emerging point-of-care technologies for sickle cell disease screening and monitoring.Are human iNKT cells keeping tabs on lipidome perturbations triggered by oxidative stress in the blood?Sickle cell disease (SCD), iNKT cells, and regadenoson infusion.Developing new pharmacotherapeutic approaches to treating sickle-cell disease.
P2860
Q27010098-6C996DBE-C656-41E2-B2AD-76507FC273FEQ27303155-5C94A184-623C-4CD3-BCFA-025C0A98FD77Q28080872-2430CEA5-AC37-4D12-9219-409A0CF76721Q28082462-655E4AF1-C356-48E7-9862-328D7D4058F7Q28088552-05402E63-356C-44BF-9DF6-BE44F68D6C97Q29346491-D7A58536-F92C-4513-BA9D-203906A04547Q34302295-09477C79-8CA6-4D19-A30F-E6BDAF000C83Q35006438-7C855C9D-777A-46EA-8F02-5810218DA9B9Q35127172-29D2DF5F-94D4-4E36-B5E8-FB53841CC977Q35987700-EC335148-D3A5-46F4-8B61-DBA066618480Q36005345-0CFBBB4A-2F6B-41BF-9BA4-4BCFC51E281AQ36171037-D687AF20-67F1-4274-A308-E5C806BE83DBQ36596850-36D628FA-9144-44E4-95D0-4941310854E6Q36596855-71BD42A7-9D84-4777-8A89-A0EFE3A72A36Q36797240-1F494C40-DD85-4CED-8EFB-41E8903D6FD7Q37031849-DE6C9786-ECEA-43AE-AECD-4A93FC1E8378Q37455225-6A2F9D8C-E6A3-43C7-96FA-E5FF160D6C2DQ38178734-0CB035B7-AC81-4A9A-9B0D-688E9745EEC8Q38289589-03DD676E-C6A6-46F8-839F-B9F9DF09A2E5Q38688814-BDC827DB-6FDB-4123-BAFB-918C7D096223Q38804432-635F8DF6-6E0F-4FAC-B7B2-252DF09E4995Q38890709-A7954B32-3D78-43B8-A2D2-381CB5318F7BQ42587651-98976E39-CC9A-4E04-8F98-4C4C602AA148Q50207951-7F1686FE-5578-4E00-B7FE-6E01F6212218
P2860
Targeting iNKT cells for the treatment of sickle cell disease.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Targeting iNKT cells for the treatment of sickle cell disease.
@ast
Targeting iNKT cells for the treatment of sickle cell disease.
@en
type
label
Targeting iNKT cells for the treatment of sickle cell disease.
@ast
Targeting iNKT cells for the treatment of sickle cell disease.
@en
prefLabel
Targeting iNKT cells for the treatment of sickle cell disease.
@ast
Targeting iNKT cells for the treatment of sickle cell disease.
@en
P2093
P2860
P1433
P1476
Targeting iNKT cells for the treatment of sickle cell disease.
@en
P2093
David G Nathan
Joel Linden
Joshua J Field
P2860
P304
P356
10.1016/J.CLIM.2011.03.002
P577
2011-03-22T00:00:00Z